Many of the region’s successful life science startups are built on technologies that were licensed from The National Institutes of Health (NIH), The National Cancer Institute (NCI), other government biomedical research institutions and Biohealth Capital Region (BHCR) research universities like Johns Hopkins and the University of Maryland.
NEW YORK, Oct. 22, 2019 /PRNewswire/ — Bloomberg Philanthropies, Johns Hopkins University School of Medicine (JHUSOM), and The New York Stem Cell Foundation (NYSCF) Research Institute today announced an initiative to fundamentally advance and expand the science of precision medicine, in which diagnostic disease markers are defined with pinpoint accuracy to help researchers understand disease pathways and customize therapeutic approaches. The collaboration will combine the renowned clinical and medical expertise of Johns Hopkins with the unique stem cell technologies and research capabilities of the NYSCF Research Institute to accelerate Hopkins’ pioneering Precision Medicine Initiatives.
Next year marks the 40th anniversary of the passage of the Bayh-Dole Act. With election day looming, 2020 is likely to be the most politically contentious year of our lifetime. The country is divided right down the middle on many fundamental issues. Rather than debate, the opposing sides often descend into personal attacks, even questioning one another’s patriotism. This isn’t the time you want issues you care about dragged into the public arena, but patent rights and the Bayh-Dole Act have been summoned into the gladiator pit. Happy birthday, indeed.
GAITHERSBURG, Md., Oct. 24, 2019 /PRNewswire/ — MaxCyte, the global cell-based therapies and life sciences company, announces today that, having completed dosing of the second cohort of patients, clinical investigators have initiated dosing in the third cohort of patients of MaxCyte’s Phase I clinical trial with the next higher cell dose of MCY-M11. This lead, wholly-owned, non-viral mRNA-based cell therapy candidate from MaxCyte’s CARMA platform is a mesothelin-targeting chimeric antigen receptor (CAR) therapy being tested in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma.
The Montgomery County Business Hall of Fame (MCBHOF) is excited to announce Dr. Robert Caret as the keynote speaker for its annual luncheon and induction ceremony on October 29.
Dr. Caret is the Chancellor of the University System of Maryland. He has held this position since 2015 where he established the priorities of access and affordability, college completion, academic and research excellence, and workforce development. Under his leadership, the USM has expanded partnerships with the business community and embraced a more entrepreneurial approach, positioning the system as vital economic and workforce engine for Maryland.
With its world-class institutions, talent and collaboration, now is the time for Maryland to take the next steps in becoming the nation’s premier science and tech-based innovation and entrepreneurial corridor.
Pocket-size ultrasound devices that cost 50 times less than the machines in hospitals (and connect to your phone). Virtual reality that speeds healing in rehab. Artificial intelligence that’s better than medical experts at spotting lung tumors. These are just some of the innovations now transforming medicine at a remarkable pace.
In March 2019, BioSpace wrote about how the BioForest Hotbed area was the fastest-growing life sciences market in the top 10 from 2014 to 2017. Although relatively small compared to the top areas such as California and Massachusetts, Washington state and Seattle are growing at faster than 17%. One of the life sciences’ heavy hitters in real estate development, Alexandria Real Estate Equities, is showing its increasing interest in the region.
Although touted as having potential to cure some of the most intractable of human illnesses, gene therapies also carry some eye-popping price tags that have threatened to limit their availability to wealthy countries. However, a new public-private partnership aims to make them available to people around the world, including in developing countries.
